Teva Ends Development of Fremanezumab in Cluster Headache

By Colin Kellaher

Teva Pharmaceutical Industries Ltd. (TEVA) on Tuesday said it is ending clinical development of fremanezumab in cluster headaches after determining a Phase 3 study in episodic cluster headaches was unlikely to meet its primary endpoint.

The Israeli pharmaceutical company said it is also ending a long-term safety study that was part of the Phase 3 program.

Teva last year discontinued a study arm of the program in chronic cluster headaches for similar reasons.

The U.S. Food and Drug Administration in December approved fremanezumab, marketed as Ajovy, for the preventive treatment of migraine in adults. Teva earlier this month said the European Commission granted similar approval for Ajovy.

Teva said it will continues to explore other uses for fremanezumab, including the treatment of post-traumatic headache.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

April 23, 2019 10:55 ET (14:55 GMT)

Teva Pharmaceutical Indu... (NYSE:TEVA)
Historical Stock Chart
From Mar 2024 to Apr 2024